gd2 car t cells
Cell therapyexperimental
Clinical trial activity
16 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 6, 2014 (NCT02107963)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Diffuse Intrinsic Pontine Glioma · Phase 1
- Drugs, Investigational · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Leukemia, Myeloid · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Neuroblastoma · Phase 2
- Osteosarcoma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 1/Phase 2
- Sarcoma, Ewing · Phase 1/Phase 2
- Sarcoma, Synovial · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
Mechanism of action
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-gd2-car engineered t cells
- anti-gd2 cart
- gd2-targeted car-t cells
- gd2 t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07211737 | Phase 1 | Nov 30, 2025 | Baylor University |
| NCT06684639 | Early Phase 1 (Phase 1) | Dec 1, 2024 | People's Liberation Army of China, Yake Biotechnology Ltd. |
| NCT05990751 | Phase 1 | Jan 31, 2024 | University of London |
| NCT05544526 | Phase 1 | Dec 31, 2022 | University of London |
| NCT04539366 | Phase 1 | Jun 11, 2021 | Cancer Immunotherapy Trials Network, National Cancer Institute (NCI) |
| NCT04196413 | Phase 1 | Apr 30, 2020 | CureSearch, Stanford University |
| NCT04099797 | Phase 1 | Dec 31, 2019 | Baylor University |
| NCT03635632 | Phase 1 | Dec 31, 2018 | Baylor University |
| NCT03638206 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2018 | Shenzhen BinDeBio Ltd., Zhengzhou University |
| NCT03373097 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2017 | Bambino Gesù Hospital and Research Institute |
| NCT02919046 | N/A | Sep 1, 2016 | Fudan University, Nanjing Medical University, Sinobioway Cell Therapy Co., Ltd. |
| NCT02765243 | Phase 2 | May 1, 2016 | Shenzhen Geno-Immune Medical Institute, Southern Medical University |
| NCT03252171 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2015 | Jinan University |
| NCT04406610 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Jinan University |
| NCT01953900 | Phase 1 | Apr 1, 2014 | Baylor University, Methodist Cancer Center, Houston, Texas, National Cancer Institute (NCI) |
| NCT02107963 | Phase 1 | Feb 6, 2014 | National Cancer Institute (NCI) |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 4 | 4 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 3 | 2 | 1 | 2014 |
| Jinan University | Academic/Hospital | 2 | 2 | 1 | 2015 |
| University of London | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Bambino Gesù Hospital and Research Institute | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Cancer Immunotherapy Trials Network | Academic/Hospital | 1 | 0 | 1 | 2021 |
| CureSearch | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2024 |
| Shenzhen BinDeBio Ltd. | For profit | 1 | 1 | 1 | 2018 |
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Sinobioway Cell Therapy Co., Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Southern Medical University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Yake Biotechnology Ltd. | Government | 1 | 0 | 1 | 2024 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2018 |
18 organizations
Page 1 / 1